Aurobindo Pharma Limited (NSE:AUROPHARMA)

Aurobindo Pharma Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Operating Revenue	369,575	336,531	317,237	290,019	248,554	234,555
Other Revenue	-445.7	-	-	-	-	-
Revenue	369,129	336,531	317,237	290,019	248,554	234,555
Revenue Growth	13.53%	6.08%	9.38%	16.68%	5.97%	-5.33%
Cost of Revenue	150,197	139,875	134,839	129,857	116,417	104,499
Gross Profit	218,932	196,656	182,399	160,162	132,137	130,056
Selling, General & Admin	58,793	52,468	45,470	40,434	36,560	35,751
Other Operating Expenses	83,465	75,068	70,603	60,894	58,083	49,976
Operating Expenses	161,696	145,142	131,985	116,247	107,018	96,992
Operating Income	57,236	51,514	50,414	43,915	25,119	33,064
Interest Expense	-3,632	-3,523	-4,404	-2,681	-1,290	-368.4
Interest & Investment Income	3,314	3,314	3,564	2,883	1,485	349.7
Earnings From Equity Investments	-65.3	15.2	-316.9	-171.6	-116.7	-312.5
Currency Exchange Gain (Loss)	408.1	-100.7	-226.5	387.8	-	699.6
Other Non Operating Income (Expenses)	2,797	1,236	1,962	1,672	974.6	1,028
EBT Excluding Unusual Items	60,057	52,455	50,992	46,006	26,173	34,461
Merger & Restructuring Charges	-401.8	-	-	-986.6	-	-
Impairment of Goodwill	-	-	-96.2	-27.4	-70.3	-
Gain (Loss) on Sale of Investments	14.2	14.2	335.3	1	-	290.8
Gain (Loss) on Sale of Assets	-243	-243	-89.4	234.9	132.3	-400.2
Asset Writedown	-493	-493	-600.2	-2,834	-239.6	-1,922
Other Unusual Items	-614.4	-614.4	121.3	1,407	130.1	1,298
Pretax Income	58,319	51,119	50,663	43,800	26,125	33,727
Income Tax Expense	18,454	16,089	15,827	12,110	6,849	7,256
Earnings From Continuing Operations	39,865	35,030	34,836	31,690	19,277	26,471
Minority Interest in Earnings	36.8	17.8	23.1	40	-1.5	10.4
Net Income	39,902	35,048	34,859	31,730	19,275	26,482
Net Income to Common	39,902	35,048	34,859	31,730	19,275	26,482
Net Income Growth	16.59%	0.54%	9.86%	64.62%	-27.21%	-50.36%
Shares Outstanding (Basic)	578	581	583	586	586	586
Shares Outstanding (Diluted)	578	581	583	586	586	586
Shares Change	-0.47%	-0.36%	-0.52%	-	-	-
EPS (Basic)	69.02	60.34	59.81	54.15	32.90	45.20
EPS (Diluted)	69.02	60.34	59.81	54.15	32.90	45.19
EPS Growth	17.13%	0.89%	10.44%	64.62%	-27.21%	-50.37%

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Free Cash Flow	31,717	28,406	19,568	-3,458	-170.5	29,636
Free Cash Flow Per Share	54.87	48.91	33.57	-5.90	-0.29	50.58
Dividend Per Share	7.000	4.000	-	4.500	3.000	9.000
Dividend Growth	-	-	-	50.00%	-66.67%	125.00%
Gross Margin	59.31%	58.44%	57.50%	55.23%	53.16%	55.45%
Operating Margin	15.51%	15.31%	15.89%	15.14%	10.11%	14.10%
Profit Margin	10.81%	10.41%	10.99%	10.94%	7.75%	11.29%
Free Cash Flow Margin	8.59%	8.44%	6.17%	-1.19%	-0.07%	12.63%
EBITDA	75,348	67,796	64,906	57,641	36,344	43,114
EBITDA Margin	20.41%	20.14%	20.46%	19.88%	14.62%	18.38%
D&A For EBITDA	18,113	16,282	14,492	13,726	11,225	10,050
EBIT	57,236	51,514	50,414	43,915	25,119	33,064
EBIT Margin	15.51%	15.31%	15.89%	15.14%	10.11%	14.10%
Effective Tax Rate	31.64%	31.47%	31.24%	27.65%	26.21%	21.52%
Revenue as Reported	376,119	341,452	323,456	295,593	251,460	237,758

Data Source: S&P Global Market Intelligence Last updated: Nov 4, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 10, 2026

Data Sources Report a data error